Hinsch A, et al. - In view of the oncogenic importance of IDH1 mutations, researchers analyzed primary prostate cancer tissues with a mutation-specific antibody for the IDH1^R132H mutation. Experts noted that 0.3% of prostate cancers had an IDH1^R132H mutation and that these were mostly found to be heterogeneous. Only a very small group of prostate cancer cases could benefit from anti-IDH1 therapy.